Englander Institute for Precision Medicine

Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.

TitleThree-dimensional regulatory hubs support oncogenic programs in glioblastoma.
Publication TypeJournal Article
Year of Publication2024
AuthorsBreves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S, Kirou R, Studer L, Khurana E, Polyzos A, Fine HA, Apostolou E
JournalbioRxiv
Date Published2024 Dec 20
ISSN2692-8205
Abstract

Dysregulation of enhancer-promoter communication in the context of the three-dimensional (3D) nucleus is increasingly recognized as a potential driver of oncogenic programs. Here, we profiled the 3D enhancer-promoter networks of primary patient-derived glioblastoma stem cells (GSCs) in comparison with neuronal stem cells (NSCs) to identify potential central nodes and vulnerabilities in the regulatory logic of this devastating cancer. Specifically, we focused on hyperconnected 3D regulatory hubs and demonstrated that hub-interacting genes exhibit high and coordinated expression at the single-cell level and strong association with oncogenic programs that distinguish IDH-wt glioblastoma patients from low-grade glioma. Epigenetic silencing of a recurrent 3D enhancer hub-with an uncharacterized role in glioblastoma-was sufficient to cause concordant downregulation of multiple hub-connected genes along with significant shifts in transcriptional states and reduced clonogenicity. By integrating published datasets from other cancer types, we also identified both universal and cancer type-specific 3D regulatory hubs which enrich for varying oncogenic programs and nominate specific factors associated with worse outcomes. Genetic alterations, such as focal duplications, could explain only a small fraction of the detected hyperconnected hubs and their increased activity. Overall, our study provides computational and experimental support for the potential central role of 3D regulatory hubs in controlling oncogenic programs and properties.

DOI10.1101/2024.12.20.629544
Alternate JournalbioRxiv
PubMed ID40034649
PubMed Central IDPMC11875237
Grant ListR01 NS136475 / NS / NINDS NIH HHS / United States
T32 HD060600 / HD / NICHD NIH HHS / United States

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021